The MenAfriVac vaccine is being rolled out across the 26 nations of Africa’s meningitis belt over the course of seven years. Illustration: PATH/David Simpson.
Meningitis epidemics in Africa are most prevalent in the “meningitis belt” that stretches across sub-Saharan Africa. About 450 million people live in this area. By 2020, the MenAfriVac® vaccine is expected to protect almost the entire population of the meningitis belt—preventing 1 million cases of meningitis A, 150,000 deaths, and 250,000 cases of severe disability.
MenAfriVac is a registered trademark of Serum Institute of India Private Ltd.